NCT03307616View on ClinicalTrials.gov

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 4, 2017

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Dedifferentiated LiposarcomaRecurrent Dedifferentiated LiposarcomaRecurrent Undifferentiated Pleomorphic SarcomaResectable Dedifferentiated LiposarcomaResectable Undifferentiated Pleomorphic SarcomaUndifferentiated Pleomorphic Sarcoma
Interventions
BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER